Form 4: Samsara BioCapital Increases Stake in Neurogene Inc. Through Multiple Share Purchases

Samsara BioCapital, through its affiliated entities, has increased its holdings in Neurogene Inc. by purchasing additional shares at various price points on November 26, 2024.

Summary

• Samsara BioCapital GP, LLC, along with Samsara BioCapital, L.P., and Dr. Srinivas Akkaraju, have reported the acquisition of Neurogene Inc. common stock.
• The purchases occurred on November 26, 2024, and were made at varying prices.
• A total of 48,770 shares were acquired across multiple transactions.
• The prices ranged from $24.25 to $27.50 per share.
• The transactions increased Samsara BioCapital's indirect ownership to 1,717,127 shares.
• The shares are held by Samsara BioCapital L.P., with Samsara BioCapital GP, LLC acting as the general partner.
• Dr. Srinivas Akkaraju has voting and investment power over these shares.

Sentiment

Score: 7

Explanation: The document indicates a positive sentiment due to increased investment by a major shareholder, suggesting confidence in the company's prospects. However, it is a standard filing and does not contain any extraordinary information.

Positives

• Samsara BioCapital's increased investment signals confidence in Neurogene Inc.'s future prospects.
• The multiple purchases at increasing prices suggest a positive outlook on the company's value.
• The increased stake strengthens Samsara BioCapital's position as a significant shareholder.

Risks

• The document does not explicitly state any risks, but the share purchases could be influenced by market volatility.
• The weighted average prices indicate that the purchases were made at different price points, which could reflect market fluctuations.

Management Comments

• Samsara BioCapital GP, LLC, through its Managing Member Srinivas Akkaraju, has signed the document.

Industry Context

This filing reflects ongoing investment activity in the biotechnology sector, where firms like Samsara BioCapital actively manage their portfolios through strategic acquisitions.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders.
• The reported transactions are typical for investment firms adjusting their positions in publicly traded companies.
• The level of detail provided in the filing is consistent with SEC requirements for transparency.

Stakeholder Impact

• The increased stake by Samsara BioCapital could be viewed positively by shareholders, potentially increasing confidence in the company.
• The share purchases may have a minor positive impact on the stock price.

Key Dates

Keywords

Samsara BioCapital, Neurogene Inc., share purchase, beneficial ownership, Srinivas Akkaraju, investment, stock acquisition